FDA Approves Remibrutinib as First Treatment for Symptomatic Dermographism and Expands Use for Chronic Spontaneous Urticaria

The U.S. Food and Drug Administration (FDA) has approved Rhapsido (remibrutinib), an oral Bruton's tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines. This approval also expands its use beyond chronic spontaneous urticaria (CSU), offering a new option for patients experiencing chronic hives and itch triggered by skin friction.